1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Encephalitis - Pipeline Review, H2 2013

Encephalitis - Pipeline Review, H2 2013

  • August 2013
  • -
  • Global Markets Direct
  • -
  • 87 pages

Encephalitis - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Encephalitis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Encephalitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Encephalitis. Encephalitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Encephalitis.
- A review of the Encephalitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Encephalitis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Encephalitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Encephalitis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Encephalitis - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Encephalitis Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Encephalitis 10
Encephalitis Therapeutics under Development by Companies 12
Encephalitis Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Encephalitis Therapeutics - Products under Development by Companies 19
Encephalitis Therapeutics - Products under Investigation by Universities/Institutes 20
Companies Involved in Encephalitis Therapeutics Development 21
Sanofi-Aventis 21
Takeda Pharmaceutical Company Limited 22
CEL-SCI Corporation 23
SIGA Technologies, Inc. 24
Panacea Biotec Limited 25
Functional Genetics, Inc. 26
Palau Pharma S.A 27
AlphaVax, Inc. 28
EpiVax, Inc. 29
Wittycell S.A.S. 30
Vaxart, Inc. 31
Hawaii Biotech, Inc. 32
NasVax Ltd. 33
Prosetta Corporation 34
Vaxine Pty Ltd 35
Encephalitis - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
CEL-1000 - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
Equine Encephalitis Vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
CST-102 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
Western Equine Encephalitis Vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
japanese encephalitis vaccine (live attenuated) - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
VEE C-84 Vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
CIGB-845 - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
Anti-CD3 Mab - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
TSI-GSD-104 Vaccine - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
Inactivated Vero Cell Derived Japanese Encephalitis Vaccine - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
Japanese Encephalitis / West Nile Virus Vaccine - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
Jak3/Syk Dual Inhibitor - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
Japanese Encephalitis Vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
West Nile Vaccine - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
PolyMap - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
Drug For Bunya Virus - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
Drugs For Viral Encephalitis - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
FGI-104 - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
WTCa Adjuvant - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
WTCb Adjuvant - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
WTCn Adjuvant - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
Tick-Borne Flavivirus Vaccine - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
Vaccine Against Venezuelan Equine Encephalitis - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
Japanese Encephalitis Vaccine - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
Venezuelan Equine Encephalitis Vaccine - Drug Profile 71
Product Description 71
Mechanism of Action 71
RandD Progress 71
Erythropoeitin Derived Short Peptides - Drug Profile 72
Product Description 72
Mechanism of Action 72
RandD Progress 72
Equine Encephalitis Viruses Vaccine - Drug Profile 73
Product Description 73
Mechanism of Action 73
RandD Progress 73
Inactivated Japanese Encephalitis Viral Vaccine - Drug Profile 74
Product Description 74
Mechanism of Action 74
RandD Progress 74
Encephalitis Therapeutics - Drug Profile Updates 75
Encephalitis Therapeutics - Discontinued Products 77
Encephalitis Therapeutics - Dormant Products 78
Encephalitis - Product Development Milestones 79
Featured News and Press Releases 79
Jul 22, 2013: Biological E's Japanese Encephalitis vaccine prequalified by the World Health Organization 79
Jun 21, 2013: Valneva Receives FDA Panel Recommendation To Extend Use Of Ixiaro Vaccine To Include Travelling Individuals Aged Two Months And Above 79
May 21, 2013: Intercell Obtains Pediatric Approval For Its Japanese Encephalitis Vaccine Ixiaro In US 80
Feb 12, 2013: Intercell's Japanese Encephalitis Vaccine Obtains European Approval For Pediatric Indication 80
Dec 16, 2012: Sanofi Pasteur Launches Next Generation Japanese Encephalitis Vaccine In Thailand 81
Dec 13, 2012: Intercell Receives CHMP Positive Opinion For Ixiaro 82
Dec 10, 2012: Sanofi Pasteur Launches Imojev First Single-dose Vaccine Against Japanese Encephalitis In Australia 83
Sep 13, 2012: Intercell's Partner Biological E. Launches Japanese Encephalitis Vaccine Jeev In India 83
Feb 01, 2012: Intercell Announces Positive Results From Two Clinical Phase III Studies Supporting Pediatric Label Extension Of JE Vaccine For Children Traveling To Endemic Areas 84
Nov 10, 2011: Intercell And Biological E. Announce Approval For Japanese Encephalitis Vaccine In India 85
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 87
Disclaimer 87



List of Tables

Number of Products Under Development for Encephalitis, H2 2013 10
Products under Development for Encephalitis - Comparative Analysis, H2 2013 11
Number of Products under Development by Companies, H2 2013 13
Number of Products under Investigation by Universities/Institutes, H2 2013 14
Comparative Analysis by Late Stage Development, H2 2013 15
Comparative Analysis by Mid Clinical Stage Development, H2 2013 16
Comparative Analysis by Early Clinical Stage Development, H2 2013 17
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 18
Products under Development by Companies, H2 2013 19
Products under Investigation by Universities/Institutes, H2 2013 20
Sanofi-Aventis, H2 2013 21
Takeda Pharmaceutical Company Limited, H2 2013 22
CEL-SCI Corporation, H2 2013 23
SIGA Technologies, Inc., H2 2013 24
Panacea Biotec Limited, H2 2013 25
Functional Genetics, Inc., H2 2013 26
Palau Pharma S.A, H2 2013 27
AlphaVax, Inc., H2 2013 28
EpiVax, Inc., H2 2013 29
Wittycell S.A.S., H2 2013 30
Vaxart, Inc., H2 2013 31
Hawaii Biotech, Inc., H2 2013 32
NasVax Ltd., H2 2013 33
Prosetta Corporation, H2 2013 34
Vaxine Pty Ltd, H2 2013 35
Assessment by Monotherapy Products, H2 2013 36
Assessment by Stage and Route of Administration, H2 2013 38
Assessment by Stage and Molecule Type, H2 2013 40
Encephalitis Therapeutics - Drug Profile Updates 75
Encephalitis Therapeutics - Discontinued Products 77
Encephalitis Therapeutics - Dormant Products 78



List of Figures

Number of Products under Development for Encephalitis, H2 2013 10
Products under Development for Encephalitis - Comparative Analysis, H2 2013 11
Products under Development by Companies, H2 2013 12
Products under Investigation by Universities/Institutes, H2 2013 14
Late Stage Products, H2 2013 15
Mid Clinical Stage Products, H2 2013 16
Early Clinical Stage Products, H2 2013 17
Discovery and Pre-Clinical Stage Products, H2 2013 18
Assessment by Monotherapy Products, H2 2013 36
Assessment by Route of Administration, H2 2013 37
Assessment by Stage and Route of Administration, H2 2013 38
Assessment by Molecule Type, H2 2013 39
Assessment by Stage and Molecule Type, H2 2013 40



Companies Mentioned

Sanofi-Aventis
Takeda Pharmaceutical Company Limited
CEL-SCI Corporation
SIGA Technologies, Inc.
Panacea Biotec Limited
Functional Genetics, Inc.
Palau Pharma S.A
AlphaVax, Inc.
EpiVax, Inc.
Wittycell S.A.S.
Vaxart, Inc.
Hawaii Biotech, Inc.
NasVax Ltd.
Prosetta Corporation
Vaxine Pty Ltd

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.